Urothelial carcinoma, common in older adults, is rare in younger populations and even less common in the prostatic urethra. Advanced disease is typically managed with platinum-based chemotherapy, immune checkpoint inhibitors, and targeted therapies. However, rare presentations in young patients with aggressive disease highlight the need for innovative and personalized treatment strategies.
This case report presents a rare instance of metastatic urothelial carcinoma originating in the prostatic urethra of a 37-year-old male. Initial symptoms led to diagnosis through imaging, biopsy, and genetic profiling, revealing mutations in TP53 and RB1. The patient underwent multiple treatments, including dose-dense chemotherapy, pembrolizumab immunotherapy, and targeted antibody-drug conjugates (Enfortumab Vedotin and Sacituzumab Govitecan). Despite aggressive therapies, disease management remained challenging, leading to experimental treatments, including a personalized vaccine.
This case underscores the importance of precision medicine and the need for innovative treatment options for rare and aggressive cancers.
Anticancer research. 2025 Feb [Epub]
Daniela Guevara, Nara Shin, Alexandra Boiko, Ivan Valiev, Ahmed G Elsaeed, Juan Miguel Mosquera, Majd Al Assaad, Jyothi Manohar, Michael Sigouros, Alisa Zaichikova, Victoria Fomchenkova, Leysan Yunusova, Sofia Smirnova, Olivier Elemento, David Nanus, Cora N Sternberg
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, U.S.A., BostonGene Corporation, Waltham, MA, U.S.A., Department of Medicine, Weill Cornell Medicine, New York, NY, U.S.A., Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, U.S.A. .